All In Biotech

Drug Trial Radar · NCT01613118

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

Efficacy and Safety of Sparsentan (RE-021), a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study

Last checked: Nov 19, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 109 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

109

Actual

Start

Mar 2014

Primary completion

Jun 2016

Study completion Mar 25, 2024

Sponsor

Lead sponsor
Travere Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 6, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 8 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate whether RE-021 (Sparsentan), a selective dual-acting receptor antagonist with affinity for endothelin (A type) and angiotensin II receptors (Type 1), is safe and effective in treating patients with focal segmental glomerulosclerosis (FSGS).

Conditions

  • Focal Segmental Glomerulosclerosis

Interventions

  • RE-021 (Sparsentan)Drug

    Oral, once-daily

  • IrbesartanDrug

    Oral, once-daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Urine Protein/Creatinine (Up/C)Time frame: 8 weeks

Locations

33 sites in 3 countries. Site status is shown where the registry gives one.

  • Balboa Nephrology Medical Group

    San Diego, California

  • Los Angeles Biomedical Research Institute

    Torrance, California

  • Colorado Kidney Care

    Denver, Colorado

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Miami Children's Hospital

    Miami, Florida

  • University of Iowa Children's Hospital

    Iowa City, Iowa

  • Renal and Transplant Associates of New England, PC

    Springfield, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • The Children's Mercy Hospital

    Kansas City, Missouri

  • NYU Langone Medical Center

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • SUNY Stony Brook Hospital

    Stony Brook, New York

  • UNC Kidney Center, Pediatrics

    Chapel Hill, North Carolina

  • University North Carolina (UNC) Kidney Center

    Chapel Hill, North Carolina

  • Akron Nephrology Associates

    Akron, Ohio

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • Unversity of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Northeast Clinical Research Center

    Bethlehem, Pennsylvania

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Temple University School of Medicine

    Philadelphia, Pennsylvania

  • University of Pennsylvania, Perelman School of Medicine

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Clinical Advancement Center

    San Antonio, Texas

  • Southern Utah Kidney and Hypertension Center

    St. George, Utah

  • University of Washington

    Seattle, Washington

  • Catholic Health Initiatives Franciscan

    Tacoma, Washington

  • Marshfield Clinic Research Foundation

    Marshfield, Wisconsin

  • General Teaching Hospital Prague

    Prague, Czechia

  • Azienda Ospedaliero Universitaria Policlinico di Bari

    Bari, Italy

  • Azienda Ospedaliero Universitaria Careggi

    Florence, Italy

  • IRCCS Istituti Clinici Maugeri

    Pavia, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Rome, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.